The in vitro activities of eight antifungal drugs against clinical isolates of Fonsecaea pedrosoi (n ‫؍‬ 21), Fonsecaea monophora (n ‫؍‬ 25), and Fonsecaea nubica (n ‫؍‬ 9) were tested. The resulting MIC 90 s for all strains (n ‫؍‬ 55) were as follows, in increasing order: posaconazole, 0.063 g/ml; itraconazole, 0.125 g/ml; isavuconazole, 0.25 g/ml; voriconazole, 0.5 g/ml; amphotericin B, 2 g/ml; caspofungin, 2 g/ml; anidulafungin, 2 g/ml; and fluconazole, 32 g/ml.
Fonsecaea spp., anamorph members of the order Chaetothyriales (black yeasts and other melanized fungi), are principal agents of human chromoblastomycosis (16) , a chronic cutaneous and subcutaneous infection characterized by slowly expanding skin lesions, a granulomatous immune response, and the presence of meristematic melanized muriform fungal cells in tissue scrapings (4) . The last characteristic is a crucial diagnostic indicator that tends to be similar irrespective of the fungal pathogen. Chromoblastomycosis occurs worldwide in tropical and subtropical climates. Fonsecaea spp. are recoverable from environmental sources, so the disease is considered to be of traumatic origin (8, 9) . The taxonomy of the genus Fonsecaea has been reviewed recently (12) , and on the basis of sequence data, the following three species are recognized: Fonsecaea pedrosoi, Fonsecaea monophora, and Fonsecaea nubica. These species are morphologically identical, but their clinical spectra differ slightly: F. pedrosoi and F. nubica appear to be associated strictly with chromoblastomycosis, whereas F. monophora has also been isolated from brain abscesses, cervical lymph nodes, and bile (4, 13, 18) .
Therapy for chromoblastomycosis is challenging because there is no consensus regarding the treatment of choice. Several treatment options have been applied, but these tend to result in protracted disease, low cure rates, and frequent relapses (5, 9, 10, 16, 18) . The therapeutic outcomes are variable and are allegedly dependent on the site of infection, lesion size, the etiological agent, and the patient's health status (4) . The specific identification of the causative pathogen is important for epidemiological reasons. The vast majority of cases of chromoblastomycosis in which the pathogen has been identified are caused by F. pedrosoi; for example, F. pedrosoi was isolated from 94% (66/69 cases) of patients with chromoblastomycosis in Sri Lanka (2) and from 98% (77/78 cases) of patients with culture-positive chromoblastomycosis in Brazil (17) .
The present study aimed at determining the in vitro susceptibilities of clinical isolates of Fonsecaea spp. to seven marketed antifungal drugs and the experimental 1,2,4-triazole antimycotic isavuconazole (11) .
Fifty-five Fonsecaea strains were obtained from the Centraalbureau voor Schimmelcultures (Utrecht, The Netherlands) and comprised 21 F. pedrosoi strains, 25 F. monophora strains, and 9 F. nubica strains. Fifty isolates originated from patients with chromoblastomycosis, one isolate was recovered from a patient with a cerebral infection, two isolates were from diseased animals, and two isolates were clinical isolates from unknown sources. Seventeen strains came from southern China, 30 from South and Central America, and 8 from other countries (The Netherlands, Spain, Uruguay, Libya, France, United Kingdom). Strain identities were verified by sequencing the ribosomal internal transcribed spacer (ITS), tubulin (TUB1), and actin (ACT1) regions. In vitro susceptibility was determined as described in CLSI document M38-A2 (6) . Briefly, the isolates were cultured on potato dextrose agar (35°C) for up to 7 days, and inocula were prepared by gently scraping the surface of the fungal colonies with a sterile cotton swab moistened with sterile physiological saline containing 0.05% Tween 40. Large particles in the cell suspensions were allowed to settle for 3 to 5 min at room temperature, and then the concentration of spores in the supernatant was adjusted spectrophotometrically (530 nm) to a percent transmission in the range 68 to 71, corresponding to 1.5 ϫ 10 4 to 4 ϫ 10 4 CFU/ml, as controlled by quantitative colony counts (6 Table 1 . For each drug-species pair, the MIC 50 and geometric mean MIC values differed by Ͻ1 log 2 dilution step, indicating that in all cases the MIC 50 obtained by inspection reasonably reflected the central tendency of the antifungal susceptibility of the population. All isolates had low MICs (MIC 90 s Յ 0.5 g/ml) for POS, ITR, ISA, and VOR; less active drugs (MIC 90 s Ն 2 g/ml) were AMB, CAS, ANI, and FLU. There were no significant differences in the activities of the surveyed drugs against F. pedrosoi, F. monophora, and F. nubica. The MICs obtained in this study were similar to those obtained in other studies of Fonsecaea isolates (1, 3, 7, (14) (15) (16) 21) .
Treatment of chromoblastomycosis is difficult. In cases caused by Cladophialophora carrionii and Phialophora verrucosa, patients generally respond well to relatively low doses of most antimycotics. The in vitro susceptibilities of C. carrionii (19) , including infections caused by the species associated with chromoblastomycosis (14) . In the present study, POS had the lowest MICs among all the drugs examined, although the MIC 90 s for ITR and ISA were only 1 and 2 log 2 dilution steps higher, respectively. The experimental drug ISA possesses potent, broad-spectrum activity against the yeasts and molds implicated in serious mycoses (11) . POS, ITR, ISA, and VOR all seem to be potential candidates for use for the treatment of chromoblastomycosis, whereas echinocandins will probably have only a limited role in treatment for this indication due to their relatively high MICs and the lack of oral formulations. However, the in vitro results presented here need to be confirmed in studies with the appropriate animal models of chromoblastomycosis.
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